Overview

This trial is active, not recruiting.

Condition recurrent ovarian cancer
Sponsor Wuhan University
Start date March 2013
End date February 2015
Trial size 200 participants
Trial identifier NCT01851746, CHB2013

Summary

The purpose of this study is to evaluate the effectiveness and security of lobaplatin combined with docetaxel in treatment of the sensitive recurrent ovarian cancer.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case control
Time perspective prospective

Primary Outcomes

Measure
Evidence of the effectiveness and security of lobaplatin combined with docetaxel in treatment of the sensitive recurrent ovarian cancer.
time frame: from pre-chemotherapy to 4-6 weeks post-chemotherapy

Eligibility Criteria

Female participants from 18 years up to 70 years old.

Inclusion Criteria: 1. age between 18 and 70 years old 2. singed the information consent form 3. Expected survival time >3 months 4. Recurrence for at least 6 months after receiving initial platinum-based chemotherapy and without cytoreductive surgery indications. Exclusion Criteria: 1. Recurrence within 6 months after receiving initial platinum-based chemotherapy 2. without radiographic evidence for tumor recurrence 3. receiving other chemotherapy, hormone therapy, immunotherapy, or radiation therapy

Additional Information

Official title A Study of Docetaxel and Lobaplatin vs. Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer
Trial information was received from ClinicalTrials.gov and was last updated in May 2013.
Information provided to ClinicalTrials.gov by Wuhan University.